2021 Fiscal Year Research-status Report
Breast cancer tumors in deep tissue imaging with bi-modal NIR/MRI probe
| Project/Area Number |
21K15577
|
|---|
| Research Institution | Tokyo University of Science |
|---|
Principal Investigator |
ドアン テイキンユン 東京理科大学, 研究推進機構生命医科学研究所, 助教 (70838870)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | OTN-NIR / MRI / multimodal imaging / breast cancer / herceptin / Her 2 |
|---|
| Outline of Annual Research Achievements |
The bimodal OTN-NIR and MR imaging probe has been successfully developed. The probe is composed of GdDOTA conjugated to polymeric micelles at different ratios and locations. The fluorescence and T1 contrast enhancement effect were investigated in various media to evaluate the stability and effectiveness of the probe. The probe shows and stable fluorescence during the interaction with plasma proteins and exhibited an excellent relaxivity up to 6 folds compared to GdDOTA. The probe was applied to image the mouse using two techniques. The images show that the probe is well bright to depict the blood vessel and margin the organ during circulation. The probe can elongate the circulation and evade from the capturing by macrophage. Herceptin bound on the surface showed the good binding affinity.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
The developed bimodal organic probe exhibits a cohesive and stable manners in biological environment. These behaviors are important for the probe circulating inside the body where multiple environment changes such as pH, tonicity, diluted concentration, or plasma protein interaction can damage the structure and reduce the imaging effectiveness. The cohesion and stability of the probe can be obtained by regulating the Gd-DOTA ratios and locations, i.e., at the core border, the structure is solidified, and the bimodal properties are preserved. Moreover, the solidified probe showed an excellent T1 contrast enhancement in MRI, along with an elongating blood circulation.
The conjugating with Herceptin confirmed the presence of antibody with a high efficient binding affinity.
|
| Strategy for Future Research Activity |
1. Assessment for targeting efficiency in vitro will use two kinds of cells including SKBR 3 overexpressing of Her 2 antigen and MCF 7 low expressing of Her-2 antigen. The dependence of targeting efficiency on the structural diameters and, temperature-, dose- and time- dependence will be obtained by flow cytometry and immunofluorescence.
2. Determine the cytotoxic effect of the probe will use SKBR 3, MCF 7 to evaluate the proliferation and viabilities. The dose-dependence toxicity will be evaluated by flow cytometry and immunofluorescence.
|
| Causes of Carryover |
The budget will be paid for the materials and reagents that necessary for the experiments.
Moreover, the budget will also use for some small tools that need for the samples characterization and data analysis, as well as the equipment rental fee.
Besides, the amount will be used to pay for the service relating to paper submission such as English proofing, submission fee.
At last, the budget will be used to pay for the member fee and conference fee that the principal investigator will attend in the next fiscal years.
|
